TG Therapeutics Targets Approximately $1 Billion In Revenue While Keeping Spending Outlook Steady
U.S. BRIUMVI sales grew approximately 52% in the third quarter, with new dosing options moving through clinical trials.
TG Therapeutics, which develops and sells medicines for B-cell diseases with a focus on multiple sclerosis, raised its 2026 revenue target to approximately $1 billion from approximately $950 million Monday. The company's earnings statement kept its annual operating-expense outlook unchanged as third-quarter U.S. sales of BRIUMVI grew approximately 52% from a year earlier.
BRIUMVI Sales And Operating Profit Grow
The revised outlook puts U.S. BRIUMVI sales at approximately $915–920 million, replacing a $890–905 million range. Third-quarter U.S. sales were $232.6 million, while global revenue totaled $259.9 million.
Chairman and Chief Executive Officer Michael S. Weiss said, “With solid third-quarter performance and a strong fourth quarter anticipated, we are on track to exceed $1 billion in global revenue in 2026, less than four years after launching BRIUMVI.”
BRIUMVI is an intravenous treatment for adults with relapsing multiple sclerosis. TG sells it in the United States; Neuraxpharm handles commercialization in certain overseas markets under an agreement that pays TG milestones and royalties. Quarterly product revenue included $7.4 million of sales to Neuraxpharm, while royalties contributed $4.1 million and license, milestone and other revenue contributed $15.8 million.
Operating profit reached $85.899 million, compared with $29.365 million a year earlier. Net income was $55.5 million, or $0.35 per diluted share, against $390.9 million in the third quarter of 2025. That earlier net-income figure included an approximately $365.0 million non-recurring tax benefit from removing an accounting allowance against deferred tax assets—not from product sales.
Higher Costs, Unchanged Spending Target
TG maintained its approximately $450–500 million annual spending target for research, development, selling and administration, excluding non-cash compensation. The range includes manufacturing expenses for injected BRIUMVI and start-up costs for a secondary manufacturer.
Quarterly research and development expenses rose to approximately $51.3 million from $40.9 million, driven primarily by manufacturing work and clinical trials. Selling and administrative expenses reached approximately $80.7 million, against $63.4 million, as marketing, media and personnel costs increased.
TG repurchased approximately $100 million of stock during the quarter: approximately 2.0 million shares at an average price of $49.43. Through the third quarter, its repurchases across all programs totaled $300 million for 8.9 million shares, approximately 6% of shares outstanding, at an average $33.88.
Cash, cash equivalents and investment securities totaled $556.7 million at September 30, 2026. Management expects those resources, together with projected BRIUMVI revenue, to cover its current operating plan.
New Ways To Give BRIUMVI
TG's next major development milestone is a late-stage readout for BRIUMVI injected under the skin, expected around year-end 2026 or early 2027. The fully enrolled trial is testing quarterly dosing; early-stage results showed mean drug availability above 60% relative to intravenous administration.
The company also reported late-stage results supporting a single 600-milligram starting infusion instead of the approved two-infusion regimen. Drug exposure was equivalent between the regimens, and infusion reactions were comparable, with none graded 3 or higher. TG identifies mid-2027 as a potential launch window for simplified infusion initiation and 2028 for the injected version.
Other presentations at MSToronto2026 included seven-year BRIUMVI follow-up and real-world data from 1,076 participants, of whom 99.2% remained relapse-free during treatment. Initial results for Azer-cel, a donor-derived cell therapy for progressive multiple sclerosis, covered 26 participants and showed no dose-limiting or high-grade toxicities associated with CAR T treatment.
TG is also testing BRIUMVI beyond multiple sclerosis. It reported positive early-stage injected-treatment results in myasthenia gravis and began a randomized mid-stage trial of intravenous BRIUMVI as maintenance treatment after efgartigimod induction. A separate mid-stage trial is evaluating adults with treatment-resistant schizophrenia.
The higher sales target rests on the existing infusion business; the potential simplified-infusion and injected-product launches remain ahead of it.